Women with rheumatoid arthritis have a longer disease duration before being prescribed disease-modifying antirheumatic drugs ...

A large-scale study reveals that rheumatoid arthritis patients—especially those seropositive or on DMARD therapy—face ...

AnaptysBio (ANAB) stock gains as H.C. Wainwright upgrades the stock on promising Phase 2b trial data for its rheumatoid ...

Shares of AnaptysBio were trading higher in the after-hours market following results from the company's rosnilimab trial as a treatment for patients with rheumatoid arthritis. After the bell, the ...

Favorable safety and tolerability, particularly when compared to standard of care biologics or JAKs Max response rates have not yet been observed; strict continuation criteria at three months in this ...

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes ...

Explore the potential benefits of omega-3s, curcumin, vitamin D, and probiotics for rheumatoid arthritis symptom management.

Patients with rheumatoid arthritis who discontinued methotrexate monotherapy were more likely to receive subsequent monotherapy treatment than those who had used the drug in combination with other ...

CDAI LDA (≤10) was achieved by 45% of 318 rosnilimab patients by Week 12, increasing to 69% (220 responders) across all doses ...

Individuals with RA are significantly more likely to develop sleep disorders, particularly insomnia, compared with the general population.

We treated 428 patients who had active rheumatoid arthritis despite methotrexate therapy with placebo or infliximab, a chimeric monoclonal antibody against TNF-α, in intravenous doses of 3 or 10 ...

Back to Healio When it comes to biologic therapy options, patients with rheumatoid arthritis are generally open to, and express high satisfaction with, IV treatments, according to findings ...